Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), has donated $100,000 to The American Society of Clinical Oncology (ASCO) Cancer Foundation to help support its efforts to advance cancer research, provide patients with important health information and conduct physician education programs. The donation was presented today during the 45th Annual Meeting of the American Society of Clinical Oncology in Orlando, Florida.

The American Cancer Society projected that more than 1.4 million people in the United States would be diagnosed with cancer in 2008. While the overall incidence of cancer has declined in the past several years, these statistics vary greatly by type of cancer and stage at diagnosis.

The ASCO Cancer Foundation supports educational programs of the highest quality in cancer care and prevention; facilitates the dissemination of information about cancer and cancer treatment to patients and their families; and, through its grant program, supports, encourages and recognizes excellence in clinical research in the field of oncology.

Related Health News:

1. Blue Cross Blue Shield of Michigan Foundation Wins Big at 2010 Wilmer Shields Rich Awards Program The Blue Cross Blue Shield of Michigan Foundation earned two national awards for Excellence in Communications, one gold and one silver, in the 2010...
2. Progen Technology Switches on Cancer Fighting Genes and Inhibits Tumor Growth BRISBANE, Australia, April 20 /PRNewswire-FirstCall/ — Progen Pharmaceuticals Limited (NASDAQ:PGLA) has released data that shows its epigenetic technology successfully inhibits tumor growth. The results of...
3. Gene Network Sciences Announces Brain Cancer Collaboration With M.D. Anderson CAMBRIDGE, Mass., April 14 /PRNewswire/ — Gene Network Sciences, Inc. (GNS) today announced that it has entered into a research collaboration with The University of...
4. First US Patient Randomized in ALSYMPCA Phase III Study Algeta ASA (OSE: ALGETA), the cancer therapeutics company, has recently announced that the first clinical center in the US, the Tulane Cancer Center, New Orleans,...
5. Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) has recently reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma...